3.0
17. Feb. 2012
Ehemaliger Mitarbeiter
Kenilworth, NJ
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Superb colleagues, excellent drug development programs, amazing legacy, competitive compensation, institutional knowledge still high, excellent corporate citizens, overall management has very good intentions
Kontras
patent cliff led to panicked decision making, under the heel of Wall Street, post Schering merger led to period of profound consolidation and ultimately down-sizing...few opportunities for professional growth, lacking a clear emerging markets strategy....China still seems like a mystery to upper management